mantle cell lymphoma

This page shows the latest mantle cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

Celgene’s Revlimid gets a win in late-stage lymphoma

Celgene is planning to file for approval of Revlimid in the new indication early next year, adding to its current uses in multiple myeloma, mantle cell lymphoma, and anaemia associated with ... An earlier read-out in diffuse large B-cell lymphoma (DLBCL)

Latest news

Another R&D flop for Incyte, but Jakafi keeps delivering

Meanwhile, Incyte was quick to point out that the failure of PI3K delta inhibitor INCB50465 in a form of NHL called diffuse large B cell lymphoma (DLBCL) does not affect phase ... II testing of the drug in other indications, including follicular lymphoma,
AZ expects return to growth this year after 2017 decline

Mantle cell lymphoma therapy Calquence has a long way to go before it can challenge main rival Imbruvica (ibrutinib) from Johnson &Johnson/AbbVie, but according to AZ is picking up 20%
Celgene gains French reimbursement for Revlimid in multiple myeloma

It’s been approved in combination with dexamethasone as a first-line treatment for multiple myeloma in patients who are not eligible for autologous stem cell transplant. ... However, HAS handed Revlimid ASMR V status, equating to ‘no
Janssen's Imbruvica fails to win NICE backing in lymphoma

Janssen's Imbruvica fails to win NICE backing in lymphoma. But the agency recommends it on the CDF for another type of cancer. ... Draft guidance from the cost-effectiveness body doesn’t back Imbruvica to treat mantle cell lymphoma (MCL) - an incurable,
AbbVie and Roche plan Venclexta combo filings in leukaemia

AbbVie and Roche have ambitions to extend the use of the drug into non-Hodgkin's lymphoma (NHL) and acute myeloid leukaemia (AML), picking up a breakthrough designation from the FDA ... 8bn last year in CLL, mantle cell lymphoma (MCL), Waldenström

More from news
Approximately 2 fully matching, plus 55 partially matching documents found.

Latest Intelligence

AstraZeneca: building a new ‘open innovation’ pharma company

AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writers Required – Cheshire: DOE

Associate Medical Director: Highly Competitive

Consultant Health Economics - London / Oxford: Negotiable

Medical Writers: Competitive Salary and Benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Account Director: £48, 000 - £60, 000

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Associate Director: £75, 000-90, 000

Senior Medical Writer: Competitive Salary

Associate Editorial Director – Med Comms – London: Salary TBC

Consumer Health Account Director: Circa £60, 000 Gym and More

Director, Market Access / HEOR - North-West: Negotiable

Account Director: Excellent benefits

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Scientific Director / Editorial Team Leader: Great salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer: Great salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...